Xarelto indication stays as-is

Share this article:

Too little information—or, specifically, missing information, according to Bloomberg—prompted the FDA to reject Johnson & Johnson's request to expand the indication for the company's blood thinner Xarelto.

The drugmaker wanted the drug to be used to reduce blood clots in coronary artery disease patients. Friday's rejection marked a third miss for this indication.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions